Published in PLoS One on March 23, 2015
Rapid high-yield expression of a candidate influenza vaccine based on the ectodomain of M2 protein linked to flagellin in plants using viral vectors. BMC Biotechnol (2015) 0.86
High immunogenicity of plant-produced candidate influenza vaccine based on the M2e peptide fused to flagellin. Bioengineered (2015) 0.80
A boosting skin vaccination with dissolving microneedle patch encapsulating M2e vaccine broadens the protective efficacy of conventional influenza vaccines. J Control Release (2017) 0.75
Characterization of structural and immunological properties of a fusion protein between flagellin from Salmonella and lumazine synthase from Brucella. Protein Sci (2017) 0.75
Supplementation of inactivated influenza vaccine with norovirus P particle-M2e chimeric vaccine enhances protection against heterologous virus challenge in chickens. PLoS One (2017) 0.75
Conjugation of wildtype and hypoallergenic mugwort allergen Art v 1 to flagellin induces IL-10-DC and suppresses allergen-specific TH2-responses in vivo. Sci Rep (2017) 0.75
Protein nanoparticle vaccine based on flagellin carrier fused to influenza conserved epitopes confers full protection against influenza A virus challenge. Virology (2017) 0.75
Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods (1983) 114.35
Toll-like receptors. Annu Rev Immunol (2001) 26.06
The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature (2001) 14.24
Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature (2012) 14.17
Structure and mechanism of the M2 proton channel of influenza A virus. Nature (2008) 6.79
Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science (2005) 6.48
Fcgamma receptors: old friends and new family members. Immunity (2006) 5.60
Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol (1988) 5.31
A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med (1999) 4.82
Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins. J Virol (1991) 3.29
In vitro evolution of H5N1 avian influenza virus toward human-type receptor specificity. Virology (2011) 3.19
Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc gamma RIII (CD16) deficient mice. Immunity (1996) 2.96
Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine (2007) 2.76
Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol (2004) 2.59
Bacterial flagellin is an effective adjuvant for CD4+ T cells in vivo. J Immunol (2002) 2.22
Advances in vaccine adjuvants. Nat Biotechnol (1999) 2.18
Flagellin promotes myeloid differentiation factor 88-dependent development of Th2-type response. J Immunol (2004) 2.13
Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine (2003) 2.00
Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Infect Immun (2006) 1.92
Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies. J Virol (1995) 1.88
Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J Virol (1990) 1.82
Evidence for phagocytosis of influenza virus-infected, apoptotic cells by neutrophils and macrophages in mice. J Immunol (2007) 1.82
Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol (2010) 1.79
Universal influenza A vaccine: optimization of M2-based constructs. Virology (2005) 1.76
Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine (2006) 1.74
A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity. J Infect Dis (2007) 1.68
Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design. Microbes Infect (2004) 1.58
M2e-based universal influenza A vaccine. Vaccine (2009) 1.52
An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. J Biol Chem (2008) 1.51
Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses. Infect Immun (2004) 1.49
Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2. J Virol (2005) 1.49
Identification of a sequence in human toll-like receptor 5 required for the binding of Gram-negative flagellin. J Biol Chem (2003) 1.47
Salmonella flagellin-dependent proinflammatory responses are localized to the conserved amino and carboxyl regions of the protein. J Immunol (2001) 1.46
Responses to the soluble flagellar protein FliC are Th2, while those to FliC on Salmonella are Th1. Eur J Immunol (2004) 1.38
Two nonadjacent regions in enteroaggregative Escherichia coli flagellin are required for activation of toll-like receptor 5. J Biol Chem (2002) 1.37
Improved design and intranasal delivery of an M2e-based human influenza A vaccine. Vaccine (2006) 1.32
Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Mol Ther (2012) 1.31
IgA immunodeficiency leads to inadequate Th cell priming and increased susceptibility to influenza virus infection. J Immunol (2001) 1.31
Gram-negative flagellin-induced self-tolerance is associated with a block in interleukin-1 receptor-associated kinase release from toll-like receptor 5. J Biol Chem (2002) 1.26
Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge. Immunol Lett (2004) 1.26
Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge. J Virol (2008) 1.22
Soluble flagellin, FliC, induces an Ag-specific Th2 response, yet promotes T-bet-regulated Th1 clearance of Salmonella typhimurium infection. Eur J Immunol (2011) 1.21
Direct stimulation of tlr5+/+ CD11c+ cells is necessary for the adjuvant activity of flagellin. J Immunol (2009) 1.20
Intranasal immunization with synthetic recombinant vaccine containing multiple epitopes of influenza virus. Vaccine (2002) 1.19
Induction of adaptive immunity by flagellin does not require robust activation of innate immunity. Eur J Immunol (2009) 1.19
Evaluation of a truncated recombinant flagellin subunit vaccine against Campylobacter jejuni. Infect Immun (1999) 1.19
Superior efficacy of a recombinant flagellin:H5N1 HA globular head vaccine is determined by the placement of the globular head within flagellin. Vaccine (2009) 1.16
Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse. Virol J (2007) 1.15
A universal epitope-based influenza vaccine and its efficacy against H5N1. Vaccine (2009) 1.14
Mucosal adjuvant activity of flagellin in aged mice. Mech Ageing Dev (2008) 1.12
Mucosal administration of flagellin protects mice from Streptococcus pneumoniae lung infection. Infect Immun (2010) 1.12
A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa. Infect Immun (2009) 1.12
A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in mice. Viral Immunol (2010) 1.11
Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection. Eur J Immunol (2012) 1.09
Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza. PLoS One (2011) 1.08
Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection. PLoS One (2010) 1.06
Intranasal administration of synthetic recombinant peptide-based vaccine protects mice from infection by Schistosoma mansoni. Infect Immun (1999) 1.05
Immunogenicity and efficacy of flagellin-fused vaccine candidates targeting 2009 pandemic H1N1 influenza in mice. PLoS One (2011) 1.05
Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections. Vaccine (2012) 1.01
Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection. Vaccine (2011) 0.99
Cell-associated flagella enhance the protection conferred by mucosally-administered attenuated Salmonella Paratyphi A vaccines. PLoS Negl Trop Dis (2011) 0.99
Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice. Vaccine (2011) 0.97
Molecular and functional characteristics of the Fcalpha/muR, a novel Fc receptor for IgM and IgA. Springer Semin Immunopathol (2006) 0.91
Immunogenicity and protective efficacy of candidate universal influenza A nanovaccines produced in plants by Tobacco mosaic virus-based vectors. Curr Pharm Des (2013) 0.89
Increased immunogenicity and protective efficacy of influenza M2e fused to a tetramerizing protein. PLoS One (2012) 0.88
Plant-produced recombinant influenza vaccine based on virus-like HBc particles carrying an extracellular domain of M2 protein. Biochemistry (Mosc) (2012) 0.88
A molecular assembly system for presentation of antigens on the surface of HBc virus-like particles. Virology (2012) 0.87
Delivery of woodchuck hepatitis virus-like particle presented influenza M2e by recombinant attenuated Salmonella displaying a delayed lysis phenotype. Vaccine (2010) 0.87
An M2e-based synthetic peptide vaccine for influenza A virus confers heterosubtypic protection from lethal virus challenge. Virol J (2013) 0.85
Broader neutralizing antibodies against H5N1 viruses using prime-boost immunization of hyperglycosylated hemagglutinin DNA and virus-like particles. PLoS One (2012) 0.84
Implication of nanoparticles/microparticles in mucosal vaccine delivery. Expert Rev Vaccines (2007) 0.84
In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran. Virology (2012) 0.83
TLR5-dependent immunogenicity of a recombinant fusion protein containing an immunodominant epitope of malarial circumsporozoite protein and the FliC flagellin of Salmonella Typhimurium. Mem Inst Oswaldo Cruz (2011) 0.81
Regulation of Toll-like receptor 5 gene expression and function on mucosal dendritic cells. PLoS One (2012) 0.80
Immunoglobulin-A antibodies in upper airway secretions may inhibit intranasal influenza virus replication in mice but not protect against clinical illness. Scand J Immunol (2005) 0.80
Virus-like particles containing the tetrameric ectodomain of influenza matrix protein 2 and flagellin induce heterosubtypic protection in mice. Biomed Res Int (2013) 0.80
Development of Recombinant Vaccine against A(H1N1) 2009 Influenza Based on Virus-like Nanoparticles Carrying the Extracellular Domain of M2 Protein. Acta Naturae (2010) 0.77